---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-050532"
form_type: "8-K"
ticker: "SHPH"
cik: "0001757499"
company_name: "Shuttle Pharmaceuticals Holdings, Inc."
filed_at: "2026-11-06T22:25:10+00:00"
generated_at: "2026-11-06T22:26:10.710547+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Shuttle Pharmaceuticals engages Bush & Associates as new auditor, replacing Forvis Mazars

## Summary
- Audit Committee and full Board approved dismissal of Forvis Mazars, LLP, effective after filing of the Form 10-Q for the quarter ended September 30, 2026.
- Bush & Associates CPA LLC engaged November 2, 2026 under an engagement letter dated October 19, 2026; Audit Committee approved in October 2026.
- New auditor will audit FY ending December 31, 2026 financials and review interim quarters ending March 31, June 30 and September 30, 2027.
- Company reports no disagreements with Forvis Mazars and no reportable events under Item 304(a)(1)(iv)/(v); no consultations with Bush & Associates in FY2024-2025 or interim period.
- Signed by Christopher Cooper, Co-Chief Executive Officer, and dated November 6, 2026.

## SEC filing metadata
- accession: 0001493152-26-050532
- form_type: 8-K
- ticker: SHPH
- cik: 0001757499
- company_name: Shuttle Pharmaceuticals Holdings, Inc.
- filed_at: 2026-11-06T22:25:10+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 4.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1757499/000149315226050532/0001493152-26-050532-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1757499/000149315226050532/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-050532
- JSON: https://secwatch.observer/filing/0001493152-26-050532.json
- Plain text: https://secwatch.observer/filing/0001493152-26-050532.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.